Positive and negative per cent agreement rates in two studies with (123I)ioflupane scans12
3-year European multicentre study with repeat (123I)ioflupane study in subjects with PS18 (Patients with early signs and/or symptoms and diagnostically uncertain PS) | Multicentre study in subjects with established diagnosis of PS or ET39 (Patients with established diagnoses of PS or ET) | |||
---|---|---|---|---|
Positive per cent agreement (95% CI) among subjects with PS; N=71 (% subjects with abnormal (123I)ioflupane images) | Positive per cent agreement (95% CI) among subjects with PS; N=158 (% subjects with abnormal (123I)ioflupane images) | |||
Reader A (n=99) | 78 (66 to 87) | Reader A (n=185) | 93 (88 to 97) | |
Reader B (n=99) | 78 (66 to 87) | Reader B (n=185) | 97 (93 to 99) | |
Reader C (n=99) | 79 (67 to 88) | Reader C (n=185) | 96 (92 to 99) | |
Reader D (n=185) | 92 (87 to 96) | |||
Reader E (n=185) | 94 (90 to 97) | |||
Negative per cent agreement (95% CI) among subjects with non-PS; N=28 (% subjects with normal (123I)ioflupane images) | Negative per cent agreement (95% CI) among subjects with non-PS; N=27 (% subjects with normal (123I)ioflupane images) | |||
Reader A (n=99) | 97 (83 to 100) | Reader A (n=185) | 96 (81 to 100) | |
Reader B (n=99) | 97 (83 to 100) | Reader B (n=185) | 74 (54 to 89) | |
Reader C (n=99) | 97 (83 to 100) | Reader C (n=185) | 85 (66 to 96) | |
Reader D (n=185) | 93 (76 to 99) | |||
Reader E (n=185) | 93 (76 to 99) |
ET, Essential tremor; PS, Parkinsonian syndrome.